Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis
Acadia Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 4, 2026
Acadia Pharmaceuticals Appoints Carl Segerstrom as Chief People Officer